Category: Clinical

Month: 16 Aug 2012

Issue: not yet available

Genentech / Roche obtain approval for Lucentis to treat DME

Roche (SIX: RO, ROG; OTCQX: RHHBY) have announced the FDA approval of Lucentis (ranibizumab injection) 0.3mg for the treatment of diabetic macular edema (DME). The approval of the successful Genentech drug follows on from the results of two identically-designed parallel, double masked, sham treatment control Phase III trials (“RIDE” and “RISE”) conducted in a total of 759 patients. In their press release, Roche heralded the regulatory approval as the “first major treatment advance in more than 25 years for [the] sight-threatening condition” of DME.

Back to previous

Related News

Gearoid Tuohy

editor

by Dr. Gearóid Tuohy   Dear EURETINA Members,   A very warm welcome to the December 4th, 2017 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue our delivery of up-to-date summary briefs on a range of topics of interest to retinal clinicians, specialists and researchers across Europe. This resource is […]